ArticleJournal of clinical and diagnostic research : JCDR2013
Cardiovascular disease risk in schizophrenia patients: a case control study.
Article in Journal of clinical and diagnostic research : JCDR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A significant causal association between C-reactive protein levels and schizophrenia.Scientific reports · 2016Pooled it
- C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.Molecular psychiatry · 2016Pooled it
- Is increased inflammation in schizophrenia associated with increased cardiovascular risk and the etiopathogenesis of this disorder?Brain, behavior, & immunity - health · 2026Article
- Mental Disorders as Risk Factors for New Onset Cardiovascular Diseases.Biomedicines · 2026Review
- Long-term traditional Chinese medicine use and incidence of metabolic syndrome in schizophrenia: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Cardiovascular Diseases and Schizophrenia in India: Evidence, Gaps, and Way Forward.Frontiers in psychiatry · 2021Review
- Higher risk of major adverse cardiac events after acute myocardial infarction in patients with schizophrenia.Open heart · 2020Observational
- Atherogenic Lipid Ratios Related to Myeloperoxidase and C-Reactive Protein Levels in Psychotic Disorders.Frontiers in psychiatry · 2020Article
- Recording of cardiovascular risk factors by general practitioners in patients with schizophrenia.Annals of general psychiatry · 2020Article
- Association between C-reactive protein and risk of schizophrenia: An updated meta-analysis.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Schizophrenia patients are at higher risk for cardiovascular morbidity and mortality. The aim of this case-control study is to measure Cardiovascular Disease (CVD) risk parameters in patient group and compare it with normal population. METHODOLOGY: We recruited 45 cases of Schizophrenia diagnosed by diagnostic and statistical manual of mental disorders (DSM-IV) criteria and 41 healthy controls from general population. The body mass index, metabolic syndrome parameters, lipid parameters and high sensitive C-reactive protein were measured in both groups. Metabolic syndrome and dyslipidemia prevalence were assessed based on National Cholesterol Education Programme (NCEP) Adult Treatment Panel III (ATP III) guidelines.
resultsThe Schizophrenia subjects showed statistically significant high waist circumference, increased triglycerides and decreased HDL cholesterol values. The subjects also showed statistically significant increased hs-CRP values. The prevalence of metabolic syndrome and laboratory dyslipidemia were 28.8% and 51.1% respectively, which were higher compared to control group.
conclusionThe Schizophrenia subjects are at higher risk for cardiovascular disease events due to high prevalence of metabolic syndrome and dyslipidemia. These patients should be regularly monitored for CVD risk factors and timely referred to physician for further management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.